Source: https://ir.diamedica.com/sec-filings/content/0001437749-19-001263/xiao20190122_sc13g.htm?TB_iframe=true&height=auto&width=auto&preload=false
Timestamp: 2019-04-18 14:33:11+00:00

Document:
The name of the issuer is DiaMedica Therapeutics Inc. (the “Issuer”).
The address of the principal executive offices of the Issuer is 2 Carlson Parkway, Suite 260, Minneapolis, MN 55447.
The principal business address of each of the Reporting Persons is Level 54 Hopewell Centre, 183 Queen’s Road East, Hong Kong.
Hermeda is a Hong Kong corporation. Mr. Xiao is a citizen of China.
The class of equity securities to which this Statement relates are the voting common shares, no par value per share, of the Issuer (the “Common Shares”).
The CUSIP number of the Common Shares is 25253X 20 7.
(a) ☐ Broker or dealer registered under Section 15 of the Act.
(b) ☐ Bank, as defined in Section 3(a)(6) of the Act.
(c) ☐ Insurance company, as defined in Section 3(a)(19) of the Act.
(d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940.
(e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
(f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g) ☐ A parent holding company or control person, in accordance with §240.13d-1(b)(1)(ii)(G).
(h) ☐ A savings association, as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) ☐ A church plan, that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
(j) ☐ A non-US institution in accordance with §240.13d-1(b)(1)(ii)(J).
(k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.
Amount beneficially owned: Hermeda is the record owner of 1,000,000 Common Shares of the Issuer. Mr. Xiao is the record owner of 15,100 Common Shares of the Issuer which includes 3,850 Common Shares issuable upon settlement of deferred share units and options to purchase an aggregate of 8,000 Common Shares, of which 3,250 shares are currently exercisable or exercisable within 60 days. Mr. Xiao, a managing director of Hermeda, has sole voting and dispositive power over the Common Shares held by Hermeda.
Percent of class: Hermeda: 8.4% and Mr. Xiao: 8.4%. The foregoing percentages are calculated based on 11,956,874 Common Shares represented to be outstanding by the Issuer on January 8, 2019.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ☐.
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required on Schedule 13G need be filed with respect to ownership by each of the undersigned of the Common Shares of DiaMedica Therapeutics Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

References: §240
 §240
 §240
 §240
 §240
 §240